Singlera Genomics signed a research and distribution agreement with EU‑based Pure Medical to commercialize its mTitan and mGuard cell‑free DNA methylation assays across several European countries. The pact includes collaborative clinical studies with universities and hospital networks to evaluate Singlera’s methylation‑based early cancer detection tests. Singlera said the agreement supports its European strategy to scale affordable early cancer detection and monitoring. The companies will work on regulatory and clinical validation activities regionally; Singlera’s COO framed the deal as a step toward making inexpensive cfDNA screening more accessible to clinicians and health systems in western Europe.